The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals.
The drug, Journavx, or suzetrigine, was approved to treat moderate to severe acute, or short-term, pain in adults. Experts say the drug, which is billed as nonaddictive, could reduce the number of opioids patients are prescribed after surgery or be used by patients who can’t take other pain medications — though several told NBC News they would like to see more research.
In a statement, Dr. Jacqueline Corrigan-Curay, the acting director of the FDA's Center for Drug Evaluation and Research, called the approval “an important public health milestone in acute pain management.”
Read Full Article Here
FDA approves new type of nonopioid painkiller for acute pain
- by: Antonio Pequeño IV
- 01.30.25
- Source:
NBC News
- 01/31/2025
Follow us
Read our latest news on any of these social networks!
Get latest news delivered daily!
We will send you breaking news right to your inbox
Have a tip? Let us know!
Recent Articles
- by: Akshay Syal, M.D
- Source:
NBC News
- 05/09/2025
FDA approves at-home HPV test to screen for cervical cancer
Traditional tests are done during a pelvic exam in the doctor’s office, an experience that many women find uncomfortable.
- by: Breitbart London
- Source:
Breitbart
- 05/09/2025
Ukraine Parliament Ratifies Trump’s Rare Earths Mineral Deal
KYIV, Ukraine (AP) – Ukraine’s Parliament unanimously voted in favor of ratifying of a landmark minerals deal with the U.S. on Thursday afternoon, a lawmaker said.
- by: David K. Li
- Source:
NBC News
- 05/09/2025
Luigi Mangione's legal defense fund hits $1 million in donations
Organizers said the financial milestone came from over 28,000 donations, with a median contribution of $20.
- by: Tobias Burns
- Source:
The Hill
- 05/08/2025
Fed holds rates steady despite pressure from Trump
The Federal Reserve’s interest rate setting committee held rates steady Wednesday at a range of 4.25 percent to 4.5 percent, despite calls from President Trump to lower borrowing costs amid price pressures from his trade war.